Chen, Yunxin http://orcid.org/0000-0001-9039-3474
Gopalakrishnan, Sathish Kumar
Ooi, Melissa
Sultana, Rehena
Lim, Li Hui
Grigoropoulos, Nicholas http://orcid.org/0000-0002-8033-5024
Ong, Shin Yeu http://orcid.org/0000-0003-0192-6975
Xu, Mingge
Teh, Ee Mei
Tan, Melinda
Ng, Lawrence
Lee, Yuh Shan
Phipps, Colin
Lim, Francesca Lorraine W. Y.
Hwang, William
Chng, Wee Joo http://orcid.org/0000-0003-2578-8335
Goh, Yeow Tee http://orcid.org/0000-0002-7069-0997
Nagarajan, Chandramouli http://orcid.org/0000-0001-5755-2226
,
Funding for this research was provided by:
Amgen Inc. | Onyx Pharmaceuticals (ISS 20159882, ISS 20159882, ISS 20159882)
Article History
Received: 18 April 2021
Revised: 11 August 2021
Accepted: 17 August 2021
First Online: 3 September 2021
Competing interests
: Y.C., S.G. and C.N. report grants from Amgen during the conduct of the study. W.J.C. reports grants from Celgene, Janssen, ASLAN. Y.C., W.J.C., C.N. reports personal fees from Amgen, Janssen, BMS. W.J.C. reports personal fees from Abbvie, Novartis, Kyan. C.N. reports personal fees for Abbvie, Astra Zeneca, and Takeda. Other authors declare no competing interests.